Premium
VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4‐YEAR FOLLOW‐UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY
Author(s) -
AlSawaf O.,
Zhang C.,
Robrecht S.,
Tandon M.,
Panchal A.,
Fink A.M.,
Tausch E.,
Ritgen M.,
Kreuzer K.A.,
Kim S.,
Wendtner C.,
Eichhorst B.,
Stilgenbauer S.,
Jiang Y.,
Hallek M.,
Fischer K.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.49_2880
Subject(s) - obinutuzumab , venetoclax , medicine , chronic lymphocytic leukemia , interquartile range , ven , bendamustine , clinical endpoint , minimal residual disease , oncology , gastroenterology , chlorambucil , randomized controlled trial , surgery , leukemia , cyclophosphamide , chemotherapy , computer security , computer science